Biotech & MedTech News
-
Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options
March 26, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Company”), announces that…
-
FendX Technologies Announces Second Closing of Non-Brokered Private Placement and Announces Further Upsizing to $2 million
March 25, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA
March 25, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera…
-
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
March 22, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX and McMaster Collaborate on NSERC Alliance Grant Application for Pathogen-Repelling Spray Nanotechnology Scale-up Development
March 15, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a…
-
Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug Development
March 13, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”), announces a…
-
FendX Announces Warrant Exercises and Share for Debt Settlement
March 13, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a…
-
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
March 7, 2024 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
DIAGNOS Announces Grant of Stock Options
March 4, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement
March 4, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”) and Applied Pharmaceutical…
